Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.

Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge. Cancers Head Neck. 2020; 5:3.

View in: PubMed